Evidence map›Paper›PMID 28498352›Full record

ArticleNanomaterials (Basel, Switzerland)2017

Encapsulation of 16-Hydroxycleroda-3,13-Dine-16,15-Olide in Mesoporous Silica Nanoparticles as a Natural Dipeptidyl Peptidase-4 Inhibitor Potentiated Hypoglycemia in Diabetic Mice.

Po-Kai Huang, Shi-Xiang Lin, May-Jywan Tsai, Max K Leong, Shian-Ren Lin, Ranjith Kumar Kankala, Chia-Hung Lee, Ching-Feng Weng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Silica-Based Nanomaterials for Diabetes Mellitus Treatment.Bioengineering (Basel, Switzerland) · 2022
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Po-Kai HuangDepartment of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan. kevin7699402@hotmail.com.
Shi-Xiang LinDepartment of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan. scujameslin@hotmail.com.
May-Jywan TsaiNeural Regeneration Laboratory, Neurological Institute, Taipei Veterans General Hospital, Taipei 11217, Taiwan. mjtsai2@vghtpe.gov.tw.
Max K LeongDepartment of Chemistry, National Dong Hwa University, Hualien 97401, Taiwan. leong@gms.ndhu.edu.tw.
Shian-Ren LinDepartment of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan. d9813003@gms.ndhu.edu.tw.
Ranjith Kumar KankalaCollege of Chemical Engineering, Huaqiao University, Xiamen 361021, China. ranjithkankala@hqu.edu.cn.
Chia-Hung LeeDepartment of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan. chlee016@gms.ndhu.edu.tw.
Ching-Feng WengDepartment of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan. cfweng@gms.ndhu.edu.tw.
National Dong Hwa University · TWHuaqiao University · CNTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural supplements comprise good efficacy with less adverse effects as against diabetic therapy, but their advancement as anti-diabetic agents is unsatisfactory with regard to the delivery system. Dipeptidyl peptidase-4 (DPP4)/CD26) can degrade glucagon-like pepetide-1 (GLP-1) which renders a decrease of blood glucose levels. 16-hydroxycleroda-3,13-dine-16,15-olide (HCD) extracted from Polyalthia longifolia, exhibits numerous medicinal potentials including hypoglycemic potential. On consideration of HCD application, the bioavailability is affected by low solubility. Extended experiments of anti-diabetic efficacy confirmed HCD biocompatible with mesoporous silica nanoparticles (MSNs) encapsulation resulted in a sustained release property in delivering HCD for the inhibition of DPP4 via the activity and protein levels of DPP4 analysis. In the enzymatic activity assay, MSN-HCD directly changed DPP4 activity. Moreover, MSN-HCD nanoparticles were treated with Caco-2 cells and the protein levels of DPP4 determined within the cells. The results revealed that MSN-HCD caused reduction of DPP4 activity in a time- and dose-dependent fashion. Orally administered MSN-HCD in diet-induced diabetic mice alleviated blood glucose via an oral glucose tolerance test. In addition, administration of MSN-HCD for five weeks revealed that the biochemical cues such as pyruvate transaminase (GPT), glutamate oxaloacetate transaminase (GOT), triglycerides (TG), cholesterol (CHO), and glycated hemoglobin (HbA1c) in mice were commendable as further confirmation of MSN-HCD efficacy and less adverse effects in down-regulation of hyperglycemia. Furthermore, this formulation effectively controlled blood glucose and significantly decreased the body weight of mice, suggesting that MSN-HCD exerts natural DPP4 inhibitor as a potential clinical drug for the treatment of diabetes.

Indexed as

diabetesdipeptidyl peptidase-4glucagon-like peptide-1 (GLP-1)glycated hemoglobin (HbA1c)insulin resistancemesoporous silica nanoparticles

Identifiers

PMID28498352
PMCPMC5449993
OpenAlexW2613540483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.